Aortic sclerosis, aortic stenosis and lipid-lowering therapy

Area of Science:

• Cardiology
• Vascular Biology
• Pharmacology

Background:

• Calcific aortic stenosis (AS) was historically viewed as degenerative, but is now understood as an active inflammatory process similar to atherosclerosis.
• Shared risk factors and pathological mechanisms link AS and atherosclerosis, including inflammation, lipid infiltration, and endothelial dysfunction.

Purpose of the Study:

• To evaluate the potential benefit of statin therapy in managing calcific aortic stenosis.
• To investigate whether statins can slow the progression of AS, particularly in patients with specific risk factors.

Main Methods:

• Review of histopathologic studies and clinical trials examining the relationship between AS, atherosclerosis, and statin use.
• Analysis of prospective randomized trials like SALTIRE and RAAVE, considering patient selection criteria (e.g., hyperlipidemia).

Main Results:

• Retrospective studies suggested statins slow AS progression, but the prospective SALTIRE trial yielded negative results, excluding hyperlipidemic patients.
• The RAAVE trial indicated rosuvastatin slowed AS progression in hypercholesterolemic patients compared to untreated individuals with normal cholesterol.

Conclusions:

• Statin therapy's benefit in calcific aortic stenosis appears limited to patients with hyperlipidemia.
• Further research is needed to clarify the role of statins in AS management, especially considering patient subgroups and specific lipid profiles.